Focused On-demand Library for Type 2 DNA topoisomerase 6 subunit B-like

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8N6T0

UPID:

TO6BL_HUMAN

Alternative names:

TOP6B like initiator of meiotic double strand breaks; Type 2 DNA topoisomerase VI subunit B-like

Alternative UPACC:

Q8N6T0; Q9H677

Background:

Type 2 DNA topoisomerase 6 subunit B-like, also known as TOP6B like initiator of meiotic double strand breaks, plays a crucial role in meiotic recombination. It is a component of a topoisomerase 6 complex that, alongside SPO11, mediates DNA cleavage forming double-strand breaks essential for initiating meiotic recombination. This process facilitates the relaxation and decatenation of DNA through cleavage and ligation cycles.

Therapeutic significance:

The protein's involvement in Hydatidiform mole, recurrent, 4, a disorder characterized by abnormal pregnancies, underscores its potential as a target for therapeutic intervention. Understanding the role of Type 2 DNA topoisomerase 6 subunit B-like could open doors to potential therapeutic strategies.